Patents by Inventor Richard Kriwacki
Richard Kriwacki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220177457Abstract: Various compounds and pharmaceutically acceptable salts thereof are provided capable of binding cyclin-dependent kinase inhibitor 1B. The compounds can have a structure according to Formula I or Formula II as detailed herein. The compounds can include SJ747, SJ749, SJ755, SJ757. Pharmaceutical formulations containing the compounds or pharmaceutically acceptable salts are also provided along with methods of use thereof. The formulations and methods can be useful for treating cancer. In some aspects, the cancer is associated with a mislocalization of the intrinsically disordered protein p27. In some aspects, the cancer is resistant to an anticancer therapy. The pharmaceutical formulation can therefore include a second active agent and/or can be given in combination with a second active agent such as a cancer therapeutic. In various aspects, methods of promoting reentry into the cell division cycle in a subject in need thereof using compounds and formulations described herein are also provided.Type: ApplicationFiled: March 12, 2020Publication date: June 9, 2022Inventors: Richard KRIWACKI, Jian ZUO, Luigi ICONARU, Sourav DAS, Anang SHELAT, Brandon YOUNG
-
Patent number: 10647702Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: November 14, 2017Date of Patent: May 12, 2020Assignee: St. Jude Children's Research HospitalInventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Royappa, Lie Min, Jaeki Min, Antonio Ferreira
-
Publication number: 20190345141Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: July 23, 2019Publication date: November 14, 2019Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
-
Publication number: 20180291004Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: November 14, 2017Publication date: October 11, 2018Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
-
Patent number: 9822100Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: January 8, 2016Date of Patent: November 21, 2017Assignee: St. Jude Children's Research HospitalInventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
-
Publication number: 20160297800Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: January 8, 2016Publication date: October 13, 2016Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
-
Patent number: 9266860Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: September 30, 2011Date of Patent: February 23, 2016Assignee: St. Jude Children's Research HospitalInventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
-
Patent number: 9249199Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R21 or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: GrantFiled: March 20, 2014Date of Patent: February 2, 2016Assignee: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Publication number: 20140248303Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R21 or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: ApplicationFiled: March 20, 2014Publication date: September 4, 2014Applicant: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Patent number: 8722055Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2i or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: GrantFiled: September 26, 2007Date of Patent: May 13, 2014Assignee: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Publication number: 20130345237Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: September 30, 2011Publication date: December 26, 2013Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Royappa, Lie Min, Jaeki Min, Anthony Ferreira
-
Publication number: 20100143394Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2i or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: ApplicationFiled: September 26, 2007Publication date: June 10, 2010Applicant: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Patent number: 7704703Abstract: The present invention discloses that the binding of Arf with Dm2, important components of the p53 tumor suppressor pathway, results in specific domains of both proteins undergoing a dramatic transition from dynamically disordered conformations to amyloid-like structures comprised of anti-parallel ?-strands. The invention exploits this discovery by providing unique methods for identifying and/or designing compounds that mimic, inhibit and/or enhance the effect of Arf on Dm2. The present invention also provides specific peptides derived from the binding domains of Arf and Dm2 which co-assemble into supramolecular structures comprised of binary anti-parallel ?-strands. The disclosed peptides may represent structural prototypes for a broader class of peptides that is capable of assembly into supramolecular structures.Type: GrantFiled: September 19, 2002Date of Patent: April 27, 2010Assignee: St. Jude Children's Research Hospital, Inc.Inventors: Richard Kriwacki, Brian Bothner, William Lewis
-
Publication number: 20040248198Abstract: The present invention discloses that the binding of Arf with Dm2, important components of the p53 tumor suppressor pathway, results in specific domains of both proteins undergoing a dramatic transition from dynamically disordered conformations to amyloid-like structures comprised of anti-parallel &bgr;-strands. The invention exploits this discovery by providing unique methods for identifying and/or designing compounds that mimic, inhibit and/or enhance the effect of Arf on Dm2. The present invention also provides specific peptides derived from the binding domains of Arf and Dm2 which co-assemble into supramolecular structures comprised of binary anti-parallel &bgr;-strands. The disclosed peptides may represent structural prototypes for a broader class of peptides that is capable of assembly into supramolecular structures.Type: ApplicationFiled: July 23, 2004Publication date: December 9, 2004Inventors: Richard Kriwacki, Brian Bothner, William Lewis
-
Publication number: 20020045192Abstract: The present invention discloses that the binding of Arf with Dm2 results in specific domains of both proteins undergoing a dramatic transition from disordered conformations to extended structures comprised of &bgr;-strands. The presence of these specific domains is necessary and sufficient for the formation of the highly stable extended &bgr; structures formed between these two proteins. The present invention further exploits this discovery by providing unique methods for identifying and/or designing compounds that mimic, inhibit and/or enhance the effect of Arf on Dm2. The present invention also provides specific protein fragments derived from Arf and Dm2 that play a critical role in the binding of these two important regulatory proteins.Type: ApplicationFiled: September 19, 2001Publication date: April 18, 2002Applicant: St. Jude Children's Research HospitalInventors: Richard Kriwacki, Brian Bothner, William Lewis